摘要
实施专利药价格谈判是提高药品可及性的有效手段,而如何选择和利用平行进口等筹码是降低谈判价格的关键问题。基于中国国情,构建专利药价格谈判的理论模型,分析开辟跨境电商主导的平行进口渠道是否以及在何种情况下有利于降低专利药的谈判价格。结果表明:当享受高医保报销比例的患者占总体患者的比重较低时,开辟跨境电商平行进口渠道不利于降低专利药的谈判价格;随着中国医疗保障体系的不断完善,未来患者享受的医保报销比例将趋于一致,届时开辟该渠道能够有效降低专利药的谈判价格。研究结论进一步夯实了中国专利药价格谈判制度的理论基础,为从跨境电商平行进口视角降低专利药谈判价格提供了政策启示。
Public agency negotiates for price drop with innovator pharmaceutical companies in order to obtain more affordable drugs.The reduction rate of negotiation price depends on how to choose and use the bargaining threat of parallel import.Based on China s actual condition,in this paper we propose an analytical model for drug pricing negotiations and explore whether and under what conditions will the threat of cross-border E-commerce parallel import can help China s public agency obtain significant price reduction.It shows that in the current situation patients are heterogeneous in terms of their insurance rate,when the proportion of patient with high insurance rate is low,such threat can not be useful in bringing down the drug price;But if patients are homogeneous in terms of their insurance rate with the improvement of China s health care system in the future,such threat can help reduce the drug price.The findings of the study further strengthen the theoretical foundation of China s drug price negotiation system,and provide policy implications for bringing down the drug price from the perspective of cross-border E-commerce parallel importation.
作者
刘婵
郭树龙
LIU Chan;GUO Shu-long
出处
《产经评论》
CSSCI
北大核心
2023年第3期20-31,共12页
Industrial Economic Review
基金
教育部人文社会科学研究青年基金项目“中国专利药价格谈判机制与政策研究”(项目编号:17YJC790091,项目负责人:刘婵)。
关键词
专利药
价格谈判
跨境电商平行进口
医保报销比例
branded drug
price negotiation
cross-border E-commerce parallel import
insurance rate
